Seres Therapeutics, Inc. MCRB
3.52
(0.10)
(2.76%)
as of 25 Sep
- Market cap
- $36.0M
- P/E
- 0.0×
Follow MCRB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
29.69 | 22.21 | 0.00 | 0.00 |
P/S ratio |
1.32 | 89.49 | 55.89 | 40.67 | |
P/FCF ratio |
0.00 | 122.63 | 0.00 | 0.00 | |
P/Operating CF |
76.39 | (8.96) | (5.20) | (3.42) | |
P/B ratio |
3.86 | 2.98 | 3.21 | 2.22 | |
Price to Tangible BV |
3.86 | 2.98 | 3.21 | 2.22 | |
EV/Sales |
1.75 | 128.00 | 103.66 | 86.82 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.69) | 168.80 | (3.74) | (3.19) | |
EV/FCF |
(9.56) | 175.40 | (3.74) | (3.19) | |
Quick Ratio |
2.16 | 2.40 | 1.55 | 2.04 | |
Current Ratio |
2.30 | 2.56 | 1.65 | 2.11 | |
Net Debt/EBITDA |
2.22 | 2.48 | 1.48 | 0.76 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.79 | 0.01 | 0.01 | 0.02 | |
Operating CF/Net income |
0.27 | 0.96 | 0.82 | (4.89) | |
Capex/Depreciation |
(0.01) | 0.19 | 0.00 | 0.02 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,594.30% | 2,667.58% | 3,685.75% | 1,241.98% | |
Selling, General and Administrative Expense of Revenue |
2,699.72% | 1,721.23% | 2,254.19% | 959.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
707.12% | 730.37% | 493.30% | 236.28% | |
Graham Net Nets |
(0.29) | (0.34) | (0.70) | (0.32) | |
Graham Number |
8.53 | 8.67 | 0.00 | 0.00 | |
Earnings Yield |
3.37% | 4.50% | (58.29%) | (30.80%) | |
Free Cash Flow Yield |
(13.87%) | 0.82% | (49.64%) | (66.93%) | |
Revenue per Share |
0.04 | 0.05 | 0.04 | 0.08 | |
Operating CF per Share |
0.25 | (1.66) | (1.71) | (2.31) | |
Capex per Share |
0.00 | 0.02 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.25 | (1.64) | (1.71) | (2.31) | |
Cash per Share |
5.44 | 5.17 | 3.11 | 1.61 | |
Shareholders Equity per Share |
4.99 | 4.99 | 2.77 | 3.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.99 | 4.99 | 2.77 | 3.56 | |
Free Cash Flow |
2.20 | (14.53) | (16.36) | (22.38) | |
Working Capital |
29.10 | 30.05 | 12.49 | 22.32 | |
Capital Expenditures |
(0.01) | 0.18 | — | 0.01 | |
Net Current Asset Value |
(48.25) | (44.60) | (59.28) | (24.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | (0.41) | 0.00 | (0.02) | |
Net Profit Margin |
2,337.32% | (3,501.14%) | (5,562.29%) | 622.42% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.69 | 1.29 | 1.50 | 13.08 | |
Average Payables |
4.97 | 2.88 | 2.25 | 1.69 | |
Average Assets |
161.11 | 139.00 | 140.90 | 122.69 | |
Average Common Equity |
33.81 | 29.00 | 38.48 | 33.74 |
Columns are period end dates